ChristopherCLagankeMD

PubMed

• Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
  Barry A Singer, Douglas L Arnold, Jelena Drulovic, Mark S Freedman, Ralf Gold, Mark Gudesblatt, Elzbieta Jasinska, Christopher C LaGanke, Robert T Naismith, Donald Neg...> ;Multiple Sclerosis. 2023 Dec 1
• 1 citations
  Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.
  Colin M Dayan, Beatriz Lecumberri, Ilaria Muller, Sashiananthan Ganesananthan, Samuel F Hunter, Krzysztof W Selmaj, Hans-Peter Hartung, Eva K Havrdova, Christopher C L...> ;Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2023 Jan 3
• 10 citations
  Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
  Alasdair J Coles, Joanne L Jones, Patrick Vermersch, Anthony Traboulsee, Ann D Bass, Aaron Boster, Andrew Chan, Giancarlo Comi, Óscar Fernández, Gavin Giovannoni, Eva ...> ;Multiple Sclerosis. 2022 Apr 1
• 33 citations
  Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
  Robert T. Naismith, Jerry S. Wolinsky, Annette Wundes, Christopher LaGanke, Douglas L. Arnold, Dragana Obradovic, Mark S. Freedman, Mark Gudesblatt, Tjalf Ziemssen, Bo...> ;Multiple Sclerosis. 2020 Nov 1
• 31 citations
  Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Ext...
  Tjalf Ziemssen, Ann D Bass, Regina Berkovich, Giancarlo Comi, Sara Eichau, Jeremy Hobart, Samuel F. Hunter, Christopher LaGanke, Volker Limmroth, Daniel Pelletier, Car...> ;CNS Drugs. 2020 Sep 1
• 6 citations
  Effect of Alemtuzumab Infusions on Vital Signs
  Angel Chinea, William David Honeycutt, Tamara Miller, Donna Graves, Alan Jacobs, Junlong Wu, Christopher LaGanke> ;International Journal of MS Care. 2020 Mar 1
• 2 citations
  The Effect of Broad-Spectrum Dietary Supplementation on Quality of Life, Symptom Severity, and Functioning in Multiple Sclerosis.
  H Reginald McDaniel, Christopher LaGanke, Laura Bloom, Sharon Goldberg, Judith Hensel, Laura A. Lantigua, Lucas C. Lages, Steven E. Atlas, Judi M. Woolger, John E. Lewis> ;Journal of Dietary Supplements. 2020 Jan 1
• 34 citations
  Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
  Adam Cuker, Ann D Bass, Congor Nadj, Mark A Agius, Brian Steingo, Krzysztof Selmaj, Timothy Thoits, Alexandre Guerreiro, Bart Van Wijmeersch, Tjalf Ziemssen, Sven G. M...> ;Multiple Sclerosis. 2020 Jan 1
• 7 citations
  The Effect of a Polysaccharide-Based Multinutrient Dietary Supplementation Regimen on Infections and Immune Functioning in Multiple Sclerosis.
  H Reginald McDaniel, Christopher LaGanke, Laura Bloom, Sharon Goldberg, Lucas C. Lages, Laura A. Lantigua, Steven E. Atlas, Judi M. Woolger, John E. Lewis> ;Journal of Dietary Supplements. 2020 Mar 3
• 12 citations
  Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
  Krista Barclay, Robert Carruthers, Anthony Traboulsee, Ann D Bass, Christopher LaGanke, Antonio Bertolotto, Aaron Boster, Elisabeth Gulowsen Celius, Jérôme De Seze, Di...> ;Frontiers in Neurology. 2019 Mar 22
• 39 citations
  Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective...
  Stanley Cohan, Harold L. Moses, Jonathan Calkwood, Carlo Tornatore, Chris LaGanke, Kyle Smoot, Venkata Meka, Macaulay Okwuokenye, Christophe Hotermans, Jason P. Mendoz...> ;Multiple Sclerosis and Related Disorders. 2018 Feb 26
• 43 citations
  Safety/tolerability of the anti-semaphorin 4D antibody VX15/2503 in a randomized phase 1 trial
  Christopher LaGanke, Lawrence Samkoff, Keith R. Edwards, Lily K. Jung Henson, Pavle Repovic, Sharon G. Lynch, Lael Stone, David Mattson, Aaron Galluzzi, Terrence L. Fi...> ;Neurology(R) Neuroimmunology & Neuroinflammation. 2017 Jun 16
• 65 citations
  Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study...
  Edward Fox, Keith R. Edwards, Gordon Burch, Daniel Wynn, Chris LaGanke, Heidi Crayton, Samuel F. Hunter, Cynthia Huffman, Edward Kim, Linda Pestreich, Kevin McCague, L...> ;Multiple Sclerosis and Related Disorders. 2014 Sep 1
• 8 citations
  Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized...
  Barry A Singer, Daniel Bandari, Mark Cascione, Christopher LaGanke, John Huddlestone, Randy Bennett, Fernando Dangond> ;BMC Neurology. 2012 Dec 6
• 2 citations
  Cross-reactive idiotypy in cerebrospinal fluid immunoglobulins in multiple sclerosis.
  Christopher C. LaGanke, Deborah W. Freeman, John N. Whitaker> ;Annals of Neurology. 2000 Jan 1
• 11 citations
  Comparison of Properties of Murine Monoclonal Anti-idiotypic Antibodies Generated with Idiotype-Bearing Monoclonal Antibodies to Myelin Basic Protein Peptides or Their...
  Shan-Ren Zhou, Qiao Han, Christopher C. LaGanke, John N. Whitaker> ;Clinical Immunology and Immunopathology. 1994 Mar 1
• 16 citations
  Multifocal motor sensory demyelinating neuropathy: inflammatory demyelinating polyradiculoneuropathy.
  Shin J. Oh, C. LaGanke, R. Powers, Gil I. Wolfe, Reade A. Quinton, Dennis K. Burns> ;Neurology. 2005 Nov 22
• Sensory Guillain-Barré syndrome.
  Oh, S. J., LaGanke, C., Claussen, G. C.> ;Neurology. 2001 Jan 9
• A cross-reactive anti-myelin basic protein idiotope in cerebrospinal fluid cells in multiple sclerosis.
  Zhou, S. R., Maier, C. C., Mitchell, G. W., LaGanke, C. C., Blalock, J. E., Whitaker, J. N.> ;Neurology. 1998 Feb
• Join now to see all